肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Lancet Oncol：PROMISE评分能为恶性胸腔积液的预后提供很好预测价值

2018-07-11 MedSci MedSci原创

胸腔积液预后
关注

英国牛津大学Psallidas等报告，PROMISE研究评分是第一个前瞻性研究验证的恶性胸腔积液的预后模型，其结合生物学和临床参数，可准确预估3个月死亡率。此评分为较好的临床预后评分，可应用于临床，提供重要的预后信息，指导合适的治疗策略选择。(Lancet Oncol. 2018年6月13日在线版) 恶性胸腔积液在全球发病率不断攀升，但有利于指导治疗和了解疾病进展潜在机制的预后标志物研究较少

英国牛津大学Psallidas等报告，PROMISE研究评分是第一个前瞻性研究验证的恶性胸腔积液的预后模型，其结合生物学和临床参数，可准确预估3个月死亡率。此评分为较好的临床预后评分，可应用于临床，提供重要的预后信息，指导合适的治疗策略选择。(Lancet Oncol. 2018年6月13日在线版) 恶性胸腔积液在全球发病率不断攀升，但有利于指导治疗和了解疾病进展潜在机制的预后标志物研究较少。PROMISE研究旨在发现、验证及评估恶性胸腔积液患者预后和胸膜固定术成功率的生物标志物，并建立预测生存的评分系统。该研究为多队列研究，采用质谱法检测患者胸液样本中蛋白质表达情况，选择临床、影像学和生物学变量构建预测模型预测3个月死亡率。 共确定了17个生存标志物和7个胸膜固定术标志物。三个独立的验证数据集(502例)分析显示，所有的胸膜固定术标志物均失败，而凝溶胶蛋白(gelsolin)、巨噬细胞迁移抑制因子、多功能蛋白聚糖和金属蛋白酶组织抑制剂1(TIMP1)可成为准确预测生存率的标志物。 8个变量(血红蛋白，C反应蛋白，白细胞计数，ECOG PS状态，肿瘤类型，胸水TIMP1浓度，以及

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829711, encodeId=82b51829e111d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 07 21:48:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865482, encodeId=71c01865482b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 21 12:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020088, encodeId=b64820200888d, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue Nov 06 05:48:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506785, encodeId=32071506e8587, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602027, encodeId=5dc9160202eed, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626484, encodeId=1628162648455, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2019-05-07 howi

    #Lancet#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1829711, encodeId=82b51829e111d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 07 21:48:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865482, encodeId=71c01865482b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 21 12:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020088, encodeId=b64820200888d, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue Nov 06 05:48:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506785, encodeId=32071506e8587, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602027, encodeId=5dc9160202eed, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626484, encodeId=1628162648455, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-10-21 minlingfeng

    #Oncol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1829711, encodeId=82b51829e111d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 07 21:48:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865482, encodeId=71c01865482b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 21 12:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020088, encodeId=b64820200888d, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue Nov 06 05:48:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506785, encodeId=32071506e8587, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602027, encodeId=5dc9160202eed, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626484, encodeId=1628162648455, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-11-06 12498a1cm67暂无昵称

    #PROM#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829711, encodeId=82b51829e111d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 07 21:48:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865482, encodeId=71c01865482b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 21 12:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020088, encodeId=b64820200888d, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue Nov 06 05:48:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506785, encodeId=32071506e8587, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602027, encodeId=5dc9160202eed, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626484, encodeId=1628162648455, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 ssnine

    #恶性胸腔积液#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829711, encodeId=82b51829e111d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 07 21:48:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865482, encodeId=71c01865482b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 21 12:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020088, encodeId=b64820200888d, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue Nov 06 05:48:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506785, encodeId=32071506e8587, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602027, encodeId=5dc9160202eed, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626484, encodeId=1628162648455, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 sunylz

    #PRO#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1829711, encodeId=82b51829e111d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 07 21:48:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865482, encodeId=71c01865482b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 21 12:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020088, encodeId=b64820200888d, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue Nov 06 05:48:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506785, encodeId=32071506e8587, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602027, encodeId=5dc9160202eed, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626484, encodeId=1628162648455, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri Jul 13 03:48:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 changjitao2016

    #预测价值#

    0

相关资讯

CHEST：小小B线知多少？

肺部超声检查中B线的存在是心源性肺水肿（CPE）和非心源性肺泡间质综合征（NCAIS）的重要特征，因此，临床医师常常难以区分这两者。近期，一项发表在杂志CHEST上的研究采用M型超声检查胸膜来鉴别心源性肺水肿与非心源性肺泡间质综合征。共有43名受试者参加了这项研究，根据病史、体格检查和图表回顾，研究者们将患者分为三组。NCAIS组、CPE组和对照组。确定了三种不同的胸膜线形态分类：连续的胸膜线；胸

PLos One：双能谱CT对良、恶性胸腔积液的鉴别诊断

在高低能量水平测得的CT值和单次光谱CT扫描中获得的有效原子序数可帮助鉴别良恶性胸腔积液。将其与患者年龄和病史相结合可进一步提高诊断性能。

赶快收藏，胸腔穿刺全面总结！

胸腔穿刺很常见，一般很简单，但是，也有不小心或者各种原因引起血气胸，甚至死亡的！所以，看似简单的胸腔穿刺，也有必要认真钻研其注意事项。

4步搞定不明原因胸腔积液诊断

第一步：回归病史，综合判断1、结合病人具体情况，考虑到底是常见病的特殊表现，还是少见病因。详细追问病史，过去的诊疗经过。2、再考虑是否一定要明确胸腔积液原因，若是预期寿命不长的恶性肿瘤，则诊断明确意义不大。不明原因胸腔积液最常见的可治疗病因是结核, 有指征的病人可以经验性抗结核治疗，无需明确病因。第二步：对获得的胸腔积液进行分析1、对胸腔积液外观进行判断（1）淡黄提示漏出液，部分为渗出液；（2）血

病例：这种胸腔积液切勿漏诊，不然后果非常严重！

导致胸腔积液的原因有很多种，常见的有炎症、结核或者肿瘤等，而今天的案例则是一种容易被误诊漏诊的病因。那么到底是什么呢？

Chest：小儿并发肺炎后住院时间延长的预测因子。

小儿社区获得性复杂性肺炎（pcacp）的特点是其临床过程延长，但这根据不同情况可能存在很大的可变性。